Advancis Pharmaceutical Corp.'s stock was pounded severely, losing more than 60 percent of its value, on news that GlaxoSmithKline plc has decided to break off the deal to use Pulsys technology with Augmentin - a project that had been aimed for Phase III trials next year and could have meant $49 million in development milestones eventually, plus $50 million in sales milestones apart from royalties. (BioWorld Today) Read More
